Document is current
Any future updates will be listed below
-
Authors
Berkovska, Olena
Schliemann, Igor
Mermelekas, Georgios
Özkan, Nazlı Ezgi
Nikpour, Mahnaz
Haakensen, Vilde Drageset
Helland, Åslaug
Lehtiö, Janne
Orre, Lukas M.
-
Funding
Funding for this research was provided by:
Helse Sør-Øst RHF (2019119)
AstraZeneca
Cancerfonden (23 2819 Pj)
Cancerfonden (25 4349 Pj)
Vetenskapsrådet (ERA PerMed 2021-00754)
Vetenskapsrådet (2024-03294)
Region Stockholm (ALF FoUI-1000396)
VINNOVA (ProMS 2024-01137)
European Commission (EU DART (965397))
Radiumhemmets Forskningsfonder (244203)
Karolinska Institutet (2023-01372)
- License Information
-
More Information
Article History
Received: 20 January 2026
Accepted: 15 May 2026
First Online: 29 May 2026
Competing interests
: L.M.O, J.L., and G.M. are shareholders of FenoMark Diagnostics that provides proteomics solutions to medical professionals, including a kit that was used in this study. Å.H. has participated in meetings (talks/advice/discussions) arranged by AbbVie, Takeda, AstraZeneca, Roche, Pfizer, Janssen, Eli Lilly, BMS, PierreFabre, Bayer, MSD, Novartis, Merck, Sanofi, Medicover, BeOne. All fees were paid to OUS. Å.H. has received support for research projects and studies from Roche, AstraZeneca, Novartis, Incyte, EliLilly, Bristol-Myers Squibb, Ultimovacs, Merck, GSK, Medicover, BeOne, and Johnson & Johnson. V.D.H. has participated in lectures organized by Bristol-Myers Squibb, MSD, AstraZeneca, Johnson&Johnson, BeOne, and Regeneron; and has participated in advisory boards of MSD, AstraZeneca, Bristol-Myers Squibb, BeOne, GSK, Immedica, Merck, and Novartis.
